D.A. Davidson & Co. Protalix Bio Therapeutics, Inc. Call Options Transaction History
D.A. Davidson & Co.
- $15.1 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PLX
# of Institutions
71Shares Held
8.62MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$3.44 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$2.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.75 Million0.0% of portfolio
-
Stratos Wealth Partners, Ltd.500KShares$1.07 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA464KShares$989,2160.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $106M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...